Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record.

Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine

Open access
Fraser, A. G., Orchard, T. R., Robinson, E. M., Jewell, D. P. · 2002 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background and aim : Data from renal transplant and rheumatoid arthritis patients suggest that there is an increased risk of malignancy after treatment with azathioprine. Whether this is true for patients with inflammatory bowel disease remains uncertain. Method : A retrospective review of clinical notes was performed. Results : Azathioprine was given to 626 of 2204 patients (855 with Crohn's disease and 1349 with ulcerative colitis). The mean total duration of azathioprine use was 27 months. The mean follow‐up from diagnosis was 13.7 years and the mean follow‐up from the start of azathioprine treatment was 6.9 years. Thirty‐one cancers were observed in 30 patients treated with azathioprine (4.5%) and 77 cancers were observed in 70 patients not treated with azathioprine (4.5%; P=N.S.). Logistic regression analysis (including in the model the age, sex, diagnosis and extent of disease) showed that treatment with azathioprine did not significantly affect the risk of the development of cancer. Eight patients had lymphoma; three had been given azathioprine (P=N.S.). For patients with ulcerative colitis, the number of colorectal cancers (including high‐grade dysplasia) in patients given azathioprine was eight of 355 (2.2%), compared with 28 of 994 (2.8%) for patients not given azathioprine (P=N.S.). The cumulative risk of colorectal cancer or dysplasia/dysplasia‐associated lesion or mass (adjusted to exclude post‐colectomy patients) after 10, 20, 30 and 40 years ofulcerative colitis was 0.4%, 1.3%, 9%and 15.5%, respectively. Conclusion : No increased risk of cancer diagnosis following azathioprine treatment was observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2002.01297.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 198

Metadata

Authors
Fraser, A. G., Orchard, T. R., Robinson, E. M., & Jewell, D. P.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2002-07
Volume
16
Issue
7
Pages
1225-1232
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2016321388
Cited by
198
References
0
FWCI
6.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. https://app.cochat.ai/papers/10.1046/j.1365-2036.2002.01297.x
The paper
Fraser, A. G., Orchard, T. R., Robinson, E. M., & Jewell, D. P. (2002). Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2002.01297.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.